1篇
您的检索式：作者名="Eric H.Kim"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia显示文摘Benign prostatic hyperplasia(BPH)is characterized by an enlarged prostate,lower urinary tract symptoms(LUTS),and a decreased urinary flow rate.Common in older men,BPH is a progressive disease that can eventually lead to complications including acute urinary retention(AUR)and the need for BPH-related surgery.Both normal and abnormal prostate growth is driven by the androgen dihydrotestosterone(DHT),which is formed from testosterone under the influence of 5-alpha reductase.Thus,5-alpha reductase inhibitors(5-ARIs)effectively reduce the serum and intraprostatic concentration of DHT,causing an involution of prostate tissue.Two 5-ARIs are currently available for the treatment of BPHdfinasteride and dutasteride.Both have been demonstrated to decrease prostate volume,improve LUTS and urinary flow rates,which ultimately reduces the risk of AUR and BPH-related surgery.Therefore,either alone or in combination with other BPH medications,5-ARIs are a mainstay of BPH management. | Eric H.Kim John A.Brockman Gerald L.Andriole | 2018 | Asian Journal of Urology2018，5，1： | 11 |
您所在的机构暂未开通此部分的功能，请联系管理员